CD8A and gastric cancer: Previous studies have shown that CD103+CD8+ T cells rather than CD103−CD8+ T cells are promising targets for immune checkpoint inhibitors.27 Consequently, we further examined whether CD103+CD8+ T cells and CD103−CD8+ T cells respond differently to PD-1 blockade in gastric cancer.